The THE EFFECT OF DONEPEZIL ON THE IMPROVEMENT OF COGNITIVE FUNCTION AND PLASMA BRAIN-DERIVED NEUROTROPHIC FACTOR (BDNF) LEVELS IN SCHIZOPHRENIA

Main Article Content

Lisal T Sonny
Lompi Fadillah Aulya
Hawaidah
Bahar Burhanuddin
Limoa Erlyn
Tammasse Jumraini
Syamsuddin Saidah

Keywords

Schizophrenia, Donepezil, Risperidone, Cognitive Function, BDNF

Abstract

Abstract


Background : Donepezil administration as adjuvant therapy in schizophrenic patients is considered to improve cognitive function and is associated with increased levels of BDNF which has been widely studied as a cognitive marker for schizophrenia. The purpose of this study was to determine the effect of Donepezil on the improvement of cognitive function and plasma BDNF levels in patients with schizophrenia.


Objective : To determine the effect of adjuvant therapy of donepezil in improving cognitive function and BDNF levels in schizophrenic patients receiving risperidone.


Method : Forty-four (44) schizophrenia inpatient were divided into two groups, the research group, and the control group. Both groups received Risperidone 4 mg/day, and only the treatment group was received 5 mg donepezil for 6 weeks. To assess cognitive function, the SCoRS v BI scale was used and plasma BDNF levels were measured. Independen t tests, Wilcoxon, Friedman and Spearman correlation tests were performed to assess the difference means between groups. 


Results : There was a significant improvement in cognitive function in both groups (p<0.05). Although there was an increase in plasma BDNF levels in both groups, only research group was statistically significant at (p<0.05). The comparison of changes in the SCoRS v BI scores, plasma BDNF levels and in the correlation in both group was significant (p <0.05).


Conclusion The addition of adjuvant therapy donepezil to standard therapy Risperidone 4 mg/day was associated with improved cognitive function and also associated with increased plasma BDNF levels.


 


 


 


 


 


 


 


 


 

Abstract 234 | Pdf Downloads 98

References

Kar,Sujita,.Meha Jain.Current understandings about cognition and the neurobiological correlates in schizophrenia. Journal of Neurosciences in Rural Practice.Vol.7.July-September2016
Kementerian Kesehatan Republik Indonesia. Riset Kesehatan Dasar. 2018
Vingerhoets,Wilhelmina A.. Bloemen,Oswald J.N.Bakker. Pharmacological interventions for the MATRICS cognitive domains in schizophrenia: what’s the evidence?. Frontiers in Psychiatry vol 4.Desember 2013(1-22)
Departemen Kesehatan Republik Indonesia. Pedoman Penggolongan dan Diagnosis Gangguan Jiwa di Indonesia III (PPDGJI-III). Jakarta, 1993 : 105-115.
Stahl SM. Stahl’s Essential Psychoparmacology. Third Edition ed. Stahl SM, editor. New York : Cambridge University Press; 2008. p. 247-325.
Iriondo MR, Salaberria K, Echeburua E. Schizophrenia: Analysis and Psychological Treatment According to the Clinical Staging. Actas Esp Psiquiatr. 2013; 41(1): p. 52-9.
Aricept®Oral Solution (Donepezil Hydrochloride). Available from http://www.accessdata.fda.gov/drugsatfda_docs/label/2004/217191bl.
Stahl SM. Stahl’s Essential Psychoparmacology. Dementia. Third Edition ed. Stahl SM, editor. New York : Cambridge University Press; 2008. p.917-929.
Sugimoto H, Ogura H, Ara Y, Limura Y, Yamanish Y. Research and Development of Donepezil Hydrochloride, a New Type of Acetylcholinesterase Inhibitor. Jpn. J.Pharmacol. 89, 7-20 (2002). p.1-20.
Xu, H., Wang, J., Zhou, Y., Chen, D., Xiu, M., Wang, L., & Zhang, X. (2021). BDNF affects the mediating effect of negative symptoms on the relationship between age of onset and cognition in patients with chronic schizophrenia. Psychoneuroendocrinology, 125. https://doi.org/10.1016/j.psyneuen.2020.105121
Vita, A., Deste, G., Barlati, S., de Peri, L., Giambra, A., Poli, R., Keefe, R. S. E., & Sacchetti, E. (2013). Interview-based assessment of cognition in schizophrenia: Applicability of the Schizophrenia Cognition Rating Scale (SCoRS) in different phases of illness and settings of care. Schizophrenia Research, 146(1–3), 217–223. https://doi.org/10.1016/j.schres.2013.02.035
Ardiningrum, W., Marchira, C. R., Kristanto, C. S., Ismanto, S. H., & Primawati, S. (2019). Uji Validitas dan Reliabilitas Cognitive Assessment Interview versi Indonesia. Cermin Dunia Kedokteran, 46(5), 327-333.
Tuǧal, Ö., Yazici, K. M., Yaǧcioǧlu, A. E. A., & Göǧüş, A. (2004). A double-blind, placebo controlled, cross-over trial of adjunctive donepezil for cognitive impairment in schizophrenia. International Journal of Neuropsychopharmacology, 7(2), 117–123. https://doi.org/10.1017/S1461145703004024
Thakurathi, N., Vincenzi, B., & Henderson, D. C. (2013). Assessing the prospect of donepezil in improving cognitive impairment in patients with schizophrenia. Expert Opinion on Investigational Drugs, 22(2), 259–265. https://doi.org/10.1517/13543784.2013.750650
Terry, A. v., & Mahadik, S. P. (2007). Time-dependent cognitive deficits associated with first and second generation antipsychotics: Cholinergic dysregulation as a potential mechanism. In Journal of Pharmacology and Experimental Therapeutics (Vol. 320, Issue 3, pp. 961–968). https://doi.org/10.1124/jpet.106.106047
Yoo, J. H., Valdovinos, M. G., & Williams, D. C. (2007). Relevance of donepezil in enhancing learning and memory in special populations: A review of the literature. In Journal of Autism and Developmental Disorders (Vol. 37, Issue 10, pp. 1883–1901). https://doi.org/10.1007/s10803-006-0322-8
Zaninotto, A. L. C., Bueno, O. F. A., Pradella-Hallinan, M., Tufik, S., Rusted, J., Stough, C., & Pompéia, S. (2009). Acute cognitive effects of donepezil in young, healthy volunteers. Human Psychopharmacology, 24(6), 453–464. https://doi.org/10.1002/hup.1044
Stryjer, R., Strous, R., Bar, F., Shaked, G., Shiloh, R., Rozencwaig, S., Grupper, D., Buchman, N., Kotler, M., Rabey, J. M., & Weizman, A. (2004). Donepezil augmentation of clozapine monotherapy in schizophrenia patients: A double blind cross-over study. Human Psychopharmacology, 19(5), 343–346. https://doi.org/10.1002/hup.595
Shrivastava, A. K., & Johnston, M. E. (2010). Cognitive neurosciences: A new paradigm in management and outcome of schizophrenia. In Indian Journal of Psychiatry (Vol. 52, Issue 2, pp. 100–105). https://doi.org/10.4103/0019-5545.64575
Sangiovanni, E., Brivio, P., Dell’Agli, M., & Calabrese, F. (2017). Botanicals as Modulators of Neuroplasticity: Focus on BDNF. Neural Plasticity, 2017. https://doi.org/10.1155/2017/5965371
Harvey, P. D., & Sand, M. (2017). Pharmacological augmentation of psychosocial and remediation training efforts in schizophrenia. In Frontiers in Psychiatry (Vol. 8, Issue SEP). Frontiers Media S.A. https://doi.org/10.3389/fpsyt.2017.00177
Mishara, A. L., & Goldberg, T. E. (2004). A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: Opening a closed book. Biological Psychiatry, 55(10), 1013–1022. https://doi.org/10.1016/j.biopsych.2004.01.027
Kotani, S., Yamauchi, T., Teramoto, T., & Ogura, H. (2008). Donepezil, an acetylcholinesterase inhibitor, enhances adult hippocampal neurogenesis. Chemico-Biological Interactions, 175(1–3), 227–230. https://doi.org/10.1016/j.cbi.2008.04.004
Carlino, D., de Vanna, M., & Tongiorgi, E. (2013). Is altered BDNF biosynthesis a general feature in patients with cognitive dysfunctions? Neuroscientist, 19(4), 345–353. https://doi.org/10.1177/1073858412469444
Buchanan, R. W., Summerfelt, A., Tek, C., & Gold, J. (n.d.). An open-labeled trial of adjunctive donepezil for cognitive impairments in patients with schizophrenia. www.elsevier.com/locate/schres
Ahmed, A. O., & Bhat, I. A. (2014). Psychopharmacological treatment of neurocognitive deficits in people with schizophrenia: A review of old and new targets. In CNS Drugs (Vol. 28, Issue 4, pp. 301–318). Springer International Publishing. https://doi.org/10.1007/s40263-014-0146-6
Ago, Y., Koda, K., Takuma, K., & Matsuda, T. (2011). Pharmacological aspects of the acetylcholinesterase inhibitor galantamine. In Journal of Pharmacological Sciences (Vol. 116, Issue 1, pp. 6–17). Japanese Pharmacological Society. https://doi.org/10.1254/jphs.11R01CR
Favalli, G., Li, J., Belmonte-de-Abreu, P., Wong, A. H. C., & Daskalakis, Z. J. (2012). The role of BDNF in the pathophysiology and treatment of schizophrenia. Journal of Psychiatric Research, 46(1), 1–11. https://doi.org/10.1016/J.JPSYCHIRES.2011.09.022
Rogers, S. L., & Friedhoff, L. T. (1998). Pharmacokinetic and pharmacodynamic profile of donepezil HCl following single oral doses. In Br J Clin Pharmacol (Vol. 46).
Gomolin, I. H., Smith, C., & Jeitner, T. M. (2011). Donepezil Dosing Strategies: Pharmacokinetic Considerations. Journal of the American Medical Directors Association, 12(8), 606–608. https://doi.org/10.1016/j.jamda.2011.02.004
Freudenreich, O., Herz, L., Deckersbach, T., Evins, A. E., Henderson, D. C., Cather, C., & Goff, D. C. (2005). Added donepezil for stable schizophrenia: A double-blind, placebo-controlled trial. Psychopharmacology, 181(2), 358–363. https://doi.org/10.1007/s00213-005-2235-1
Nieto, R., Kukuljan, M., & Silva, H. (2013). BDNF and schizophrenia: From neurodevelopment to neuronal plasticity, learning, and memory. In Frontiers in Psychiatry (Vol. 4, Issue JUN). https://doi.org/10.3389/fpsyt.2013.00045
Keefe, R. S. E., Malhotra, A. K., Meltzer, H. Y., Kane, J. M., Buchanan, R. W., Murthy, A., Sovel, M., Li, C., & Goldman, R. (2008). Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: Significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial. Neuropsychopharmacology, 33(6), 1217–1228. https://doi.org/10.1038/sj.npp.1301499
Favalli, G., Li, J., Belmonte-de-Abreu, P., Wong, A. H. C., & Daskalakis, Z. J. (2012). The role of BDNF in the pathophysiology and treatment of schizophrenia. Journal of Psychiatric Research, 46(1), 1–11. https://doi.org/10.1016/J.JPSYCHIRES.2011.09.022
Turkmen, B. A., Yazici, E., Erdogan, D. G., Suda, M. A., & Yazici, A. B. (n.d.). BDNF, GDNF, NGF and Klotho levels and neurocognitive functions in acute term of schizophrenia. https://doi.org/10.1186/s12888-021-03578-4
Zhang, B., Zhao, J., Wang, Z., Xu, L., Liu, A., & Du, G. (2020). DL0410 attenuates oxidative stress and neuroinflammation via BDNF/TrkB/ERK/CREB and Nrf2/HO-1 activation. International Immunopharmacology, 86. https://doi.org/10.1016/j.intimp.2020.106729
Khuroo, A. H., Gurule, S. J., Monif, T., Goswami, D., Saha, A., & Singh, S. K. (2012). ESI-MS/MS stability-indicating bioanalytical method development and validation for simultaneous estimation of donepezil, 5-desmethyl donepezil and 6-desmethyl donepezil in human plasma. Biomedical Chromatography, 26(5), 636–649. https://doi.org/10.1002/bmc.1709
Lin, C. H., Lin, E., & Lane, H. Y. (2017). Genetic biomarkers on age-related cognitive decline. In Frontiers in Psychiatry (Vol. 8, Issue NOV). Frontiers Media S.A. https://doi.org/10.3389/fpsyt.2017.00247
Tuǧal, Ö., Yazici, K. M., Yaǧcioǧlu, A. E. A., & Göǧüş, A. (2004). A double-blind, placebo controlled, cross-over trial of adjunctive donepezil for cognitive impairment in schizophrenia. International Journal of Neuropsychopharmacology, 7(2), 117–123. https://doi.org/10.1017/S1461145703004024
Kunitachi, S., Fujita, Y., Ishima, T., Kohno, M., Horio, M., Tanibuchi, Y., Shirayama, Y., Iyo, M., & Hashimoto, K. (2009). Phencyclidine-induced cognitive deficits in mice are ameliorated by subsequent subchronic administration of donepezil: Role of sigma-1 receptors. Brain Research, 1279, 189–196. https://doi.org/10.1016/j.brainres.2009.05.004
Sawada, H., Oeda, T., Kohsaka, M., Umemura, A., Tomita, S., Park, K., Mizoguchi, K., Matsuo, H., Hasegawa, K., Fujimura, H., Sugiyama, H., Nakamura, M., Kikuchi, S., Yamamoto, K., Fukuda, T., Ito, S., Goto, M., Kiyohara, K., & Kawamura, T. (2018). Early use of donepezil against psychosis and cognitive decline in Parkinson’s disease: A randomised controlled trial for 2 years. Journal of Neurology, Neurosurgery and Psychiatry, 89(12), 1332–1340. https://doi.org/10.1136/jnnp-2018-318107
Terry, A. v., & Mahadik, S. P. (2007). Time-dependent cognitive deficits associated with first and second generation antipsychotics: Cholinergic dysregulation as a potential mechanism. In Journal of Pharmacology and Experimental Therapeutics (Vol. 320, Issue 3, pp. 961–968). https://doi.org/10.1124/jpet.106.106047
Mitchell, E. S., & Neumaier, J. F. (2005). 5-HT6 receptors: A novel target for cognitive enhancement. In Pharmacology and Therapeutics (Vol. 108, Issue 3, pp. 320–333). https://doi.org/10.1016/j.pharmthera.2005.05.001
Stryjer, R., Strous, R., Bar, F., Shaked, G., Shiloh, R., Rozencwaig, S., Grupper, D., Buchman, N., Kotler, M., Rabey, J. M., & Weizman, A. (2004). Donepezil augmentation of clozapine monotherapy in schizophrenia patients: A double blind cross-over study. Human Psychopharmacology, 19(5), 343–346. https://doi.org/10.1002/hup.595
Chung, Y. C., Lee, C. R., Park, T. W., Yang, K. H., & Kim, K. W. (2009). Effect of donepezil added to atypical antipsychotics on cognition in patients with schizophrenia: An open-label trial. World Journal of Biological Psychiatry, 10(2), 156–162. https://doi.org/10.1080/15622970701432551
Zaninotto, A. L. C., Bueno, O. F. A., Pradella-Hallinan, M., Tufik, S., Rusted, J., Stough, C., & Pompéia, S. (2009). Acute cognitive effects of donepezil in young, healthy volunteers. Human Psychopharmacology, 24(6), 453–464. https://doi.org/10.1002/hup.1044
Yoo, J. H., Valdovinos, M. G., & Williams, D. C. (2007). Relevance of donepezil in enhancing learning and memory in special populations: A review of the literature. In Journal of Autism and Developmental Disorders (Vol. 37, Issue 10, pp. 1883–1901). https://doi.org/10.1007/s10803-006-0322-8
Scarr, E., & Dean, B. (2009). Role of the cholinergic system in the pathology and treatment of schizophrenia. In Expert Review of Neurotherapeutics (Vol. 9, Issue 1, pp. 73–86). https://doi.org/10.1586/14737175.9.1.73
Thakurathi, N., Vincenzi, B., & Henderson, D. C. (2013). Assessing the prospect of donepezil in improving cognitive impairment in patients with schizophrenia. Expert Opinion on Investigational Drugs, 22(2), 259–265. https://doi.org/10.1517/13543784.2013.750650
Vita, A., Deste, G., Barlati, S., de Peri, L., Giambra, A., Poli, R., Keefe, R. S. E., & Sacchetti, E. (2013). Interview-based assessment of cognition in schizophrenia: Applicability of the Schizophrenia Cognition Rating Scale (SCoRS) in different phases of illness and settings of care. Schizophrenia Research, 146(1–3), 217–223. https://doi.org/10.1016/j.schres.2013.02.035
Keefe, R. S., Poe, M., Trina Walker, M. M., Joseph Kang, R. W., & Philip Harvey, M. D. (2006). Article The Schizophrenia Cognition Rating Scale: An Interview-Based Assessment and Its Relationship to Cognition, Real-World Functioning, and Functional Capacity. In Am J Psychiatry (Vol. 163). www.matrics.ucla.edu
Provensi, G., Costa, A., Passani, M. B., & Blandina, P. (2016). Donepezil, an acetylcholine esterase inhibitor, and ABT-239, a histamine H3 receptor antagonist/inverse agonist, require the integrity of brain histamine system to exert biochemical and procognitive effects in the mouse. Neuropharmacology, 109, 139–147. https://doi.org/10.1016/j.neuropharm.2016.06.010
Sarter, M., Lustig, C., & Taylor, S. F. (2012). Cholinergic contributions to the cognitive symptoms of schizophrenia and the viability of cholinergic treatments. In Neuropharmacology (Vol. 62, Issue 3, pp. 1544–1553). https://doi.org/10.1016/j.neuropharm.2010.12.001
Risch, S. C., Horner, M. D., McGurk, S. R., Palecko, S., Markowitz, J. S., Nahas, Z., & DeVane, C. L. (2006). Donepezil effects on mood in patients with schizophrenia and schizoaffective disorder. International Journal of Neuropsychopharmacology, 9(5), 603–605. https://doi.org/10.1017/S1461145705006115
Miranda, M., Morici, J. F., Zanoni, M. B., & Bekinschtein, P. (2019). Brain-Derived Neurotrophic Factor: A Key Molecule for Memory in the Healthy and the Pathological Brain. In Frontiers in Cellular Neuroscience (Vol. 13). Frontiers Media S.A. https://doi.org/10.3389/fncel.2019.00363
Mazhari, S., Ghafaree-Nejad, A. R., Soleymani-Zade, S., & Keefe, R. S. E. (2017). Validation of the Persian version of the Schizophrenia Cognition Rating Scale (SCoRS) in patients with schizophrenia. Asian Journal of Psychiatry, 27, 12–15. https://doi.org/10.1016/j.ajp.2017.02.007
Li, Y. X., Ye, Z. H., Chen, T., Jia, X. F., & He, L. (2018). The effects of donepezil on phencyclidine-induced cognitive deficits in a mouse model of schizophrenia. Pharmacology Biochemistry and Behavior, 175, 69–76. https://doi.org/10.1016/j.pbb.2018.09.006
Risch, Z. Nahas, M.D. Horner, S.R. McGurk, M. Molloy, J. Goldman, C. Gilliard, S.D. Owens, S. Christie, J.S. Markowitz, C.L. DeVane, J.E. Mintzer, and M.S. George. DONEPEZIL AUGMENTATION OF ANTIPSYCHOTICS IN SCHIZOPHRENIA: COGNITIVE AND fMRI EFFECTS Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, 67 President Street, Room 502N, PO Box 250861 Charleston, SC 29425. http://dx.doi.org/10.1016/S0006-3223(00)00319-X

Most read articles by the same author(s)